Startup’s diagnostics test aims to reshape breast cancer treatment
As founder and CEO of BioArray Therapeutics Inc., a Connecticut-based cancer diagnostics startup, Marcia Fournier has heard from hundreds of breast cancer patients and their families about the physical, emotional and financial toll that chemotherapy treatments have taken on them.
“After the initial diagnosis, about 75 percent of early-stage breast cancer patients undergo chemotherapy,” she said. “There’s a lot of pain and suffering.” Of that 75 percent, Fournier said, only 25 percent will completely respond to the chemo treatment.
That prompted Fournier to ask a fundamental question: What if a patient’s response to a particular cancer treatment could be predicted?
Read the full article here.